Abstract: The present invention provides methods for selectively amplifying a target population of nucleic acid molecules in a population of RNA template molecules (e.g., all mRNA molecules expressed in a cell type except for the most highly expressed mRNA species). The invention also provides a method of generating a population of oligonucleotide primers for transcriptome profiling of total RNA from a subject of interest.

Abstract: The present invention provides methods for selectively amplifying a target population of nucleic acid molecules (e.g., all mRNA molecules expressed in a cell type except for the most highly expressed mRNA species). The present invention also provides populations of oligonucleotides including the nucleic acid sequences set forth in SEQ ID NOS:1-933. These oligonucleotides can be used, for example, to prime the synthesis of cDNA molecules complementary to mRNA molecules isolated from mammalian blood without priming the synthesis of cDNA molecules complementary to globin mRNA, or ribosomal RNA molecules.

Abstract: The present invention provides methods for selectively amplifying a target population of nucleic acid molecules in a population of RNA template molecules (e.g., all mRNA molecules expressed in a cell type except for the most highly expressed mRNA species). The present invention also provides a first population of oligonucleotides including the nucleic acid sequences set forth in SEQ ID NOS:1-749 and a second population of oligonucleotides including the nucleic acid sequences set forth in SEQ ID NOS:750-1498. The first population of oligonucleotides can be used, for example, to prime the synthesis of first strand cDNA molecules complementary to mRNA molecules isolated from mammalian cells without priming the synthesis of cDNA molecules complementary to ribosomal RNA molecules.

Abstract: The present invention provides methods for selectively amplifying a target population of nucleic acid molecules in a population of RNA template molecules (e.g., all mRNA molecules expressed in a cell type except for the most highly expressed mRNA species). The invention also provides a method of generating a population of oligonucleotide primers for transcriptome profiling of total RNA from a subject of interest.

Abstract: The present invention provides methods for selectively amplifying a target population of nucleic acid molecules (e.g., all mRNA molecules expressed in a cell type except for the most highly expressed mRNA species). The present invention also provides populations of oligonucleotides including the nucleic acid sequences set forth in SEQ ID NOS:1-933. These oligonucleotides can be used, for example, to prime the synthesis of cDNA molecules complementary to mRNA molecules isolated from mammalian blood without priming the synthesis of cDNA molecules complementary to globin mRNA, or ribosomal RNA molecules.

Abstract: The present invention features nucleic acids and polypeptides encoding novel splice variant isoform of phosphodiesterase 4B (PDE4B). The polynucleotide sequence of PDE4Bsv1 is provided by SEQ ID NO: 3. The amino acid sequence of PDE4Bsv1 is provided by SEQ ID NO: 4. The present invention also provides methods for using PDE4B polynucleotides and proteins to screen for compounds that bind to PDE4B.

Abstract: The present invention features a nucleic acid and a polypeptide encoding a novel splice variant isoform of mitotic centromere-associated kinesin (MCAK). The polynucleotide sequence of MCAKsv1 is provided by SEQ ID NO 2. The amino acid sequence for MCAKsv1 is provided by SEQ ID NO 3. The present invention also provides methods for using MCAKsv1 polynucleotide and protein to screen for compounds that bind to MCAKsv1 and to screen for compounds that bind to other kinesin isoform polypeptides but not to MCAKsv1.

Abstract: The present invention features nucleic acids and polypeptides encoding four novel splice variant isoforms of PHKA2. The polynucleotide sequences of PHKA2sv3, PHKA2sv4, PHKA2sv6 and PHKA2sv7 are provided by SEQ ID NO 1, SEQ ID NO 3, SEQ ID NO 5 and SEQ ID NO 6, respectively. The amino acid sequences for PHKA2sv3, PHKA2sv4, and PHKA2sv7 are provided by SEQ ID NO 2, SEQ ID NO 4, and SEQ ID NO 7, respectively. The present invention also provides methods for using PHKA2sv3, PHKA2sv4, and PHKA2sv7 polynucleotides and proteins to screen for compounds that bind to PHKA2sv3, PHKA2sv4, and PHKA2sv7, respectively.

Abstract: The present invention features nucleic acids and polypeptides encoding novel splice variant isoforms of acetyl-CoA carboxylase 2 (ACC2). The polynucleotide sequence of ACC2sv1 is provided by SEQ ID NO 3. The amino acid sequence of ACC2sv1 is provided by SEQ ID NO 4. The present invention also provides methods for using ACC2sv1 polynucleotides and proteins to screen for compounds that bind to ACC2sv1.

Abstract: The present invention features nucleic acids and polypeptides encoding two novel splice variant isoforms of checkpoint kinase 1 (CHK1). The polynucleotide sequences of CHK1sv1 and CHK1sv2 are provided by SEQ ID NO 3 and SEQ ID NO 5, respectively. The amino acid sequences for CHK1sv1 and CHK1sv2 are provided by SEQ ID NO 4 and SEQ ID NO 6, respectively. The present invention also provides methods for using CHK1sv1 and CHK1sv2 polynucleotides and proteins to screen for compounds that bind to CHK1sv1 and CHK1sv2, respectively.

Abstract: The present invention features nucleic acids and polypeptides encoding a novel splice variant isoform of interleukin 4, subunit alpha (IL-4R?). The polynucleotide sequence of IL-4R?sv1 is provided by SEQ ID NO 4. The amino acid sequence for IL-4R?sv1 is provided by SEQ ID NO 5. The present invention also provides methods for using IL-4R?sv1 polynucleotides and proteins to screen for compounds that bind to IL-4R?sv1.

Abstract: The present invention features nucleic acids and polypeptides encoding a novel splice variant isoform of cell division cycle 25A (Cdc25A) phosphatase. The polynucleotide sequence of Cdc25Asv1 is provided by SEQ ID NO:2. The amino acid sequence for Cdc25Asv1 is provided by SEQ ID NO:3. The present invention also provides methods for using Cdc25Asv1 polynucleotides and proteins to screen for compounds that bind to Cdc25Asv1.

Abstract: The present invention features nucleic acids and polypeptides encoding three novel splice variant isoforms of sodium channel, voltage gated, type VIII, alpha (SCN8A). The polynucleotide sequences of SCN8Asv1.1, SCN8Asv1.2 and SCN8Asv2 are provided by SEQ ID NO 3, SEQ ID NO 5, and SEQ ID NO 7, respectively. The amino acid sequences for SCN8Asv1.1, SCN8Asv1.2, and SCN8Asv2 are provided by SEQ ID NO 4, SEQ ID NO 6, and SEQ ID NO 8, respectively. The present invention also provides methods for using SCN8Asv1.1, SCN8Asv1.2, and SCN8Asv2 polynucleotides and proteins to screen for compounds that bind to SCN8Asv1.1, SCN8Asv1.2, and SCN8Asv2, respectively.

Abstract: The present invention features nucleic acids and polypeptides encoding two novel splice variant isoforms of nuclear factor kappa-B, subunit 1 (NFKB1). The polynucleotide sequences of NFKB1sv1 and NFKB1sv2 are provided by SEQ ID NO 3 and SEQ ID NO 5, respectively. The amino acid sequences for NFKB1sv1 and NFKB1sv2 are provided by SEQ ID NO 4 and SEQ ID NO 6, respectively. The present invention also provides methods for using NFKB1sv1 and NFKB1sv2 polynucleotides and proteins to screen for compounds that bind to NFKB1sv1 and NFKB1sv2, respectively.

Abstract: The present invention features nucleic acids and polypeptides encoding three novel splice variant isoforms of receptor-interacting serine-threonine kinase 2 (RIPK2). The polynucleotide sequences of RIPK2sv1.1, RIPK2sv1.2, and RIPK2s2 are provided by SEQ ID NO 1, SEQ ID NO 3, and SEQ ID NO 5, respectively. The amino acid sequences for RIPK2sv1.1, RIPK2sv1.2, and RIPK2sv2 are provided by SEQ ID NO 2, SEQ ID NO 4, and SEQ ID NO 6, respectively. The present invention also provides methods for using RIPK2sv1.1, RIPK2sv1.2, and RIPK2sv2 polynucleotides and proteins to screen for compounds that bind to RIPK2sv1.1, RIPK2sv1.2, and RIPK2sv2, respectively.

Abstract: The present invention features nucleic acids and polypeptides encoding three novel variant isoform of centromere protein E (CENPE). The polynucleotide sequence of CENPEv2, CENPEv3, and CENPEv4 are provided by SEQ ID NO 6, SEQ ID NO 8, and SEQ ID NO 10, respectively. The amino acid sequences for CENPEv2, CENPEv3, and CENPEv4 are provided by SEQ ID NO 7, SEQ ID NO 9, and SEQ ID NO 11, respectively. The present invention also provides methods for using CENPEv2, CENPEv3, and CENPEv4 polynucleotides and proteins to screen for compounds that bind to CENPEv2, CENPEv3, and CENPEv4, respectively. The present invention also provides for methods to detect the presence of cancer and for inhibiting abnormal cell proliferation.